Skip to content
AwardedCzechiaGoodsCZK 100,551,000

Selektivní Imunosupresiva - Vedolizumab_VII.

Published
Published 13 February 2026
Deadline
Closed 17 March 2026

Overview

Předmětem veřejné zakázky jsou dodávky léčivých přípravků pro intravenózní (i.v.) a subkutánní podání (s.c.) s obsahem monoklonální protilátky vedolizumab (ATC skupina L04AG05) pro léčbu pacientů ve schválených indikacích dle SPC platného ke dni podání nabídky.

Key details

Country
Czechia
Status
Awarded
Category
Goods
Estimated value
CZK 100,551,000
Procedure
Open
Published
13 February 2026
Deadline
Closed
Classification (CPV)
Immunosuppressive agents

Award outcome

Awarded value
CZK 100,550,882
Award date
20 March 2026
Contract period
— → 27 February 2030
Winner
  • Takeda Pharmaceuticals Czech Republic s.r.o.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    27 April 2026

  2. Contract Notice

    13 February 2026

Contracting authority

  • Institut klinické a experimentální medicíny

    Procuring entity

    Praha, Czechia

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Selektivní Imunosupresiva - Vedolizumab_VII. — won by Takeda Pharmaceuticals Czech Republic s.r.o. — Skim